Clinical Trial Update: RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating RE001 T cell injection for KRAS G12V-mutated solid tumors, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kras G12v-mutated Solid Tumors

Drugs mentioned

• RE001 T cell injection

Snippet

Sponsor: Henan Cancer Hospital | Conditions: KRAS G12V, T Cell Therapy | Phase 1 | Status: NOT_YET_RECRUITING